Premium
Survival outcomes of C hinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate‐specific antigen nadir level
Author(s) -
Teoh Jeremy Yuen Chun,
Tsu James Hok Leung,
Yuen Steffi Kar Kei,
Chan Samson Yun Sang,
Chiu Peter Ka Fung,
Wong KaWing,
Ho KwanLun,
Hou Simon See Ming,
Ng ChiFai,
Yiu Ming Kwong
Publication year - 2017
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12313
Subject(s) - medicine , nadir , prostate cancer , hazard ratio , prostate specific antigen , urology , androgen deprivation therapy , oncology , prostate , confidence interval , proportional hazards model , cancer , satellite , engineering , aerospace engineering
Aim To evaluate the progression‐free survival ( PFS ), cancer‐specific survival ( CSS ) and overall survival ( OS ) of C hinese metastatic prostate cancer patients following primary androgen deprivation therapy ( ADT ) in relation to prostate‐specific antigen ( PSA ) nadir level. Methods All C hinese prostate cancer patients with bone metastases who were treated with primary ADT from 2000 to 2009 were included. Patients' and disease characteristics were recorded. Patients were categorized into two PSA nadir groups (≤1.0 and >1.0 ng/mL). Associations of PSA nadir with PFS , CSS and OS were analyzed with K aplan– M eier and C ox regression analyses. The survival outcomes of the two PSA nadir groups were presented. Results Four hundred nineteen patients were included in the study. PSA nadir appeared to be a good predictor for PFS (hazard ratio [ HR ] 1.86, 95% confidence interval [ CI ] 1.35–2.56, P < 0.001), CSS ( HR 1.60, 95% CI 0.98–2.64, P = 0.063) and OS ( HR 1.77, 95% CI 1.20–2.41, P < 0.001) upon multivariate C ox regression analyses. In the PSA nadir groups of ≤1.0 and >1.0 ng/mL, the median PFS were 15 and 10 months, and the 1‐year PFS rates were 64% and 40%, respectively; the median CSS were 42 and 27 months, and the 5‐year OS rates were 53% and 28%, respectively; and the median OS were 41 and 24 months, and the 5‐year OS rates were 45% and 19%, respectively. Conclusions Higher PSA nadir was associated with shorter PFS , CSS and OS in C hinese metastatic prostate cancer patients following primary ADT . The survival outcomes may serve as references in deciding the best treatment strategy in C hinese prostate cancer patients.